TD Cowen Downgrades Avidity Biosciences to Hold, Lowers Price Target to $74
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
TD Cowen analyst Ritu Baral downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Hold and lowers the price target from $78 to $74.
TD Cowen analyst Ritu Baral downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Hold and lowers the price target from $78 to $74.